Dr. Neelapu on Managing Toxicities Associated with CAR T-Cell Products in Lymphoma
Sattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.
Dr. Neelapu on Emerging CAR T-Cell Therapies in Relapsed/Refractory MCL
Sattva Neelapu, MD, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma.
Dr. Neelapu on Potential Advantages of Allogeneic CAR T-Cell Therapy in Lymphoma
Sattva Neelapu, MD, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.
Dr. Neelapu on Third-Line CAR T-Cell Therapy in Large B-Cell Lymphoma
Sattva Neelapu, MD, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.